Latest News and Press Releases

Preparing for imminent submission of clinical trial applications (CTAs) for GalNAc-conjugated AATD candidate (WVE-006), the industry’s first RNA editing clinical candidate Novel DMD therapeutic...

CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling...

CAMBRIDGE, Mass., June 26, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling...

Potent and durable target engagement observed across cohorts, including with 10 mg doses administered every 12 weeks which were also generally safe and well-tolerated WVE-004 did not show clinical...

Presentations include new data showing WVE-006 improved markers of liver disease in mice; WVE-006 is a first-in-class RNA editing therapeutic for alpha-1 antitrypsin deficiency (AATD) which is...

Emerging leader in RNA medicines with multi-modal discovery and development platform and first-in-class RNA editing programs Rapidly advancing toward 2023 CTA submissions and first-in-human...

CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...

Published preclinical data demonstrate unprecedented Ago2 loading following administration of single subcutaneous siRNA dose, leading to improved potency and durability in vivo versus comparator siRNA...

CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...

Achieved clinical validation of PRISM platform in 2022 – demonstrated ability to potently and durably engage RNA targets and translate preclinical data to the clinic          Extended...